Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal (FAI) Insert
NCT ID: NCT05070728
Last Updated: 2024-12-19
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
12 participants
INTERVENTIONAL
2021-10-13
2023-04-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sham Comparator
Intravitreal sham injection
Sham Injector
Intravitreal sham injection
FAI insert (0.05 mg fluocinolone acetonide)
Fluocinolone acetonide (FA) intravitreal 0.05 mg insert (Yutiq 0.05 mg).
FAI Insert
Yutiq 0.05 mg contains 0.05 mg FA and was designed to deliver FA into the vitreous humor for at least 24 weeks.
Yutiq 0.05 mg was administered to the study eye by injection through the pars plana using a pre-loaded applicator with a 25-gauge needle.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sham Injector
Intravitreal sham injection
FAI Insert
Yutiq 0.05 mg contains 0.05 mg FA and was designed to deliver FA into the vitreous humor for at least 24 weeks.
Yutiq 0.05 mg was administered to the study eye by injection through the pars plana using a pre-loaded applicator with a 25-gauge needle.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. One or both eyes had a history of recurrent non-infectious uveitis affecting the posterior segment of the eye (intermediate, posterior, or panuveitis) with or without anterior uveitis \>1 year duration.
3. During the 52 weeks prior to enrollment (Day 1), the subject must have received treatment for uveitis in the study eye with:
1. Systemic corticosteroid or other systemic therapies for at least 12 consecutive or non-consecutive weeks, AND/OR
2. at least 2 intra- or peri-ocular administrations of corticosteroid in the study eye, OR
3. the study eye has experienced recurrence of uveitis at least 2 separate times requiring systemic, intra- or peri-ocular injection of corticosteroid.
4. At the time of enrollment (Day 1), the study eye has \<10 anterior chamber cells/HPF (high power field) and a vitreous haze ≤ grade 2.
5. Visual acuity of study eye ≥15 letters on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart.
6. Not planning to undergo elective ocular surgery during the study.
7. Able to understand and sign the Informed Consent Form (ICF).
8. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
Exclusion Criteria
2. History of iritis only associated with no vitreous cells, anterior chamber cells, or vitreous haze at Day 1.
3. Uveitis with infectious etiology.
4. Vitreous hemorrhage.
5. Intraocular inflammation associated with a condition other than noninfectious uveitis (eg, intraocular lymphoma).
6. Uveitis limited to the anterior segment, ie, anterior uveitis only.
7. Ocular malignancy in either eye, including choroidal melanoma.
8. Previous viral retinitis.
9. Toxoplasmosis scar or scar related to previous viral retinitis in the study eye.
10. Current viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, mycobacterial infections of the eye, or fungal diseases of ocular structures.
11. Media opacity precluding evaluation of retina and vitreous.
12. Peripheral retinal detachment in area of insertion.
13. Diagnosis of any form of glaucoma or ocular hypertension at Screening, unless previously treated with an incisional surgery procedure that has resulted in stable intraocular pressure (IOP) in the normal range \[10-21 millimeter of mercury (mmHg)\].
14. IOP \>21 mmHg or concurrent therapy at Screening with any IOP lowering pharmacologic agent.
15. Chronic hypotony (\<6 mmHg).
16. Ocular surgery within 12 weeks prior to Day 1.
17. Capsulotomy within 30 days prior to Day 1.
18. Prior intravitreal treatment with Retisert®, ILUVIEN®, or YUTIQ® (0.18 mg) within 156 weeks prior to Day 1.
19. Prior intravitreal treatment with OZURDEX® or sub-choroidal injection with XIPERE™ within 24 weeks prior to Day 1.
20. Prior intravitreal treatment with Triesence® or TRIVARIS™ within 12 weeks prior to Day 1.
21. Peri-ocular or subtenon steroid treatment within 12 weeks prior to Day 1.
22. Allergy to fluocinolone acetonide or any component of Yutiq 0.05 mg.
23. Requirement for chronic systemic or inhaled corticosteroid therapy (\>15mg prednisone daily) or chronic systemic immunosuppressive therapy.
24. History of certain skin cancers (specifically, basal cell carcinoma and squamous cell carcinoma), any malignancy receiving treatment, or in remission less than 5 years prior to Day 1.
25. Positive test for human immunodeficiency virus (HIV) or syphilis during Screening.
26. Mycobacterial uveitis or chorioretinal changes of either eye which, in the opinion of the Investigator, result from infectious mycobacterial uveitis.
27. Systemic infection within 30 days prior to Day 1.
28. Any severe acute or chronic medical or psychiatric condition that could increase the risk associated with study participation or could interfere with the interpretation of study results and, in the judgment of the Investigator, could make the subject inappropriate for study enrollment.
29. Any other systemic or ocular condition which, in the judgment of the Investigator, could make the subject inappropriate for study enrollment.
30. Treatment with an investigational drug or device within 30 days prior to Day 1.
31. Pregnant or nursing females; females of childbearing potential who are unwilling or unable to use an acceptable method of contraception as outlined in the protocol from at least 14 days prior to Day 1 until the 52-week Visit.
32. Unlikely to comply with the study protocol or who are likely to be lost to follow-up within 52 weeks.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
EyePoint Pharmaceuticals, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
EyePoint Study Site
Waltham, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EYP-2102-001
Identifier Type: -
Identifier Source: org_study_id